Valneva

Valneva CROIC

The Cash Return on Invested Capital (CROIC) of Valneva (VLA.PA) as of Oct 29, 2026 is -19.92 %. In the previous year, Cash Return on Invested Capital (CROIC) was -21.04 % — a change of -5.35% (higher).

CROIC

-19.92 %

YoY

-5.35%

Last updated:

Cash Return on Invested Capital (CROIC) of Valneva is 2025 -19.92 % . Cash Return on Invested Capital (CROIC) of Valneva was 2024 -21.04 % . It decreases by -5.35% higher compared to the previous year.

The Valneva CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
6.54 EUR
Jan 1, 2019
-2.43 EUR
Jan 1, 2020
64.67 EUR
Jan 1, 2021
-5.70 EUR
Jan 1, 2022
-73.80 EUR
Jan 1, 2023
-64.37 EUR
Jan 1, 2024
-21.04 EUR
Jan 1, 2025
-19.92 EUR
The Valneva CROIC history
YEARCROICYoY
-19.92 %-5.35%
-21.04 %-67.31%
-64.37 %-12.77%
-73.80 %+1,193.81%
-5.70 %-108.82%
64.67 %-2,761.37%
-2.43 %-137.15%
6.54 %+22.16%
5.35 %+246.29%
1.55 %-114.13%
-10.94 %+15.72%
-9.45 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valneva Stock analysis

What does Valneva do? Valneva SE is a biopharmaceutical company specializing in the development, production, and marketing of vaccines for humans and animals. The company was founded in 2013 through the merger of French biotech company Vivalis and Austrian biotech company Intercell. Valneva focuses on developing vaccines for infectious diseases with a significant global burden but limited commercial demand. They work closely with governments and international organizations to improve access to their vaccines in developing countries. Valneva also has a strong presence in the animal vaccine market, producing vaccines for diseases in livestock and pets. They have developed and marketed several vaccines, including Ixiaro for Japanese encephalitis and VLA15, a vaccine candidate for Lyme disease. Overall, Valneva is an international company with an impressive pipeline of vaccine candidates and a commitment to addressing global health needs. Valneva is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valneva stock

Cash Return on Invested Capital (CROIC) of Valneva is -19.92 % in 2025.

Cash Return on Invested Capital (CROIC) of Valneva changed from -21.04 % to -19.92 %, representing a -5.35% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Valneva since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Valneva with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Valneva

All Key Metrics — Valneva